Early Commercialization Positions RAIN as Potentially Disruptive Provider – Initiation Report

Rain Enhancement Technologies (RAIN) and Tensor Networks agreed to a binding letter of intent for a business combination, with Tensor Networks becoming part of RAIN's publicly traded holding company. The transaction is expected to close in Q1 2027, subject to closing conditions. Tensor Networks, a developer of AI infrastructure security technology, will operate as a subsidiary under RAIN, with Eric Frazier as CEO and Randy Seidl as President.

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

The article lists several tech M&A deals. Mitsubishi Electric will buy the remaining 51% of Poland’s MEDCOM, taking ownership to 100%, subject to regulatory approval, with no terms disclosed. Kingspan will acquire BMC for €850m upfront plus up to €50m deferred. Rain acquired Ansa to link stored-value wallets with Mastercard networks; terms undisclosed.

Western Union said its Stablecard combines a USDPT wallet and a USDPT-backed Visa card for spending where Visa is accepted. USDPT is a U.S. dollar stablecoin issued by Anchorage Digital on Solana. Western Union launched in 37 markets and plans over 60 by year-end. Rain provides enterprise infrastructure; Rain raised $250 million and joined Visa’s stablecoin settlement pilot.

Amazon (AMZN) CEO Andy Jassy stated that AWS cloud capacity is sold out through 2027, with significant commitments into 2028 due to high AI infrastructure demand. AWS plans $220B in 2026 capex for data centers. Jassy noted that 2026 capacity is fully committed, with most of 2027 and significant 2028 capacity reserved. AWS retains some on-demand resources for services like EC2 and Bedrock. Amazon reports Q3 earnings on October 29, with AWS growth and spending in focus.

Novartis' remibrutinib showed a 30% reduction in disability progression in a Phase III trial for multiple sclerosis (MS). The drug also increased the proportion of patients with no evidence of disease activity. Novartis estimates a $4B opportunity for remibrutinib in relapsing MS. The company reported no major safety differences compared to teriflunomide. Novartis is conducting additional studies, with results expected in 2028 and 2031.